Abstract:ETHNOPHARMACOLOGICAL RELEVANCE: Tripterygium wilfordii Hook. f. (Tripterygium wilfordii), also known as Huangteng and gelsemium elegan, is a traditional Chinese medicine that has been marketed in China as Tripterygium wilfordii glycoside tablets. Triptolide (TP), an active component in Tripterygium wilfordii extracts, has been used to treat various diseases, including lupus, cancer, rheumatoid arthritis and nephritic syndrome. This review summarizes recent developments in the research on the pharmacodynamics, pharmacokinetics, pharmacy and toxicology of TP, with a focus on its novel mechanism of reducing toxicity. This review provides insight for future studies on traditional Chinese medicine, a field that is both historically and currently important.MATERIALS AND METHODS: We included studies published primarily within the last five years that were available in online academic databases (e.g., PubMed, Google Scholar, CNKI, SciFinder and Web of Science).RESULTS: TP has a long history of use in China because it displays multiple pharmacological activities, including anti-rheumatism, anti-inflammatory, anti-tumor and neuroprotective properties. It has been widely used for the treatment of various diseases, such as rheumatoid arthritis, nephritic syndrome, lupus, Behcet׳s disease and central nervous system diseases. Recently, numerous breakthroughs have been made in our understanding of the pharmacological efficacy of TP. Although TP has been marketed as a traditional Chinese medicine, its multi-organ toxicity prevents it from being widely used in clinical practice.CONCLUSIONS: Triptolide, a biologically active natural product extracted from the root of Tripterygium wilfordii, has shown promising pharmacological effects, particularly as an anti-tumor agent. Currently, in anti-cancer research, more effort should be devoted to investigating effective anti-tumor targets and confirming the anti-tumor spectrum and clinical indications of novel anti-tumor pro-drugs. To apply TP appropriately, with high efficacy and low toxicity, the safety and non-toxic dose range for specific target organs and diseases should be determined, the altered pathways and mechanisms of exposure need to be clarified, and an early warning system for toxicity needs to be established. With further in-depth study of the efficacy and toxicity of TP, we believe that TP will become a promising multi-use drug with improved clinical efficacy and safety in the future.

Triptolide Inhibits Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Expression in Human Colon Cancer and Leukemia Cells

Triptolide Inhibit the Expression of Cyclooxygenase-2(COX-2)and Inducible Nitric Oxide Synthase(iNOS)on Human Colon Cancer Cells

Inhibition of lipopolysaccharide-induced expression of cyclooxygenase-2 in PC-12 cells by triptolide

Triptolide Inhibits the Proliferation of Cells from Lymphocytic Leukemic Cell Lines in Association with Downregulation of NF-κB Activity and Mir-16-1*.

Triptolide Down-regulates Bcr-abl Expression and Induces Apoptosis in Chronic Myelogenous Leukemia Cells

Inhibition of Hsp90 by Triptolide (tpl) Augments Bortezomib-Induced U266 Cells Apoptosis

Triptolide Down‐regulates COX‐2 Expression and PGE2 Release by Suppressing the Activity of NF‐κB and MAP Kinases in Lipopolysaccharide‐treated PC12 Cells

[Effect of Triptolide on TNFalpha-induced Activation of NF-kappaB and Expression of COX-2 and Inos in Human Rheumatoid Arthritis Synovial Fibroblasts].

[Effect of Triptolide on Human Oral Cancer Cell Proliferation and PTEN Gene Mrna Expression in Oral Cancer].

Triptolidenol, isolated from Tripterygium wilfordii, disrupted NF-κB/COX-2 pathway by targeting ATP-binding sites of IKKβ in clear cell renal cell carcinoma

Triptolide Inhibited the Invasion Ability of Pancreatic Cancer Cells Through TLR4/NF-kB Signaling Pathway

Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo

Effects of triptolide on the sphingosine kinase – Sphingosine-1-phosphate signaling pathway in colitis-associated colon cancer

Triptolide: Progress on research in pharmacodynamics and toxicology

Triptolide Induces Apoptosis and Inhibits the Growth and Angiogenesis of Human Pancreatic Cancer Cells by Downregulating COX-2 and VEGF.

Triptolide Induces hepatotoxicity via inhibition of CYP450s in Rat liver microsomes

The Anti-Tumor Mechanism and Target of Triptolide Based on Network Pharmacology and Molecular Docking

Triptolide induces apoptosis of glioma cells by inhibiting NF-κB activation during oxidative stress

Triptolide-induced in vitro and in vivo cytotoxicity in human breast cancer stem cells and primary breast cancer cells.

Triptolide Inhibits Proinflammatory Factor-Induced Over-Expression of Class Ii Mhc and B7 Molecules in Renal Tubular Epithelial Cells

Triptolide Down-Regulates Tumor Necrosis Factor-Α and Interferon-Γ-induced Overexpression of Monocyte Chemoattractant Protein-1 in Human Proximal Tubular Epithelial Cells